Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis

Zhang, Qingqian; Qian, Yue; Yin, Ying

doi:10.1007/s00228-021-03187-w

Cited by 5 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no signi cant difference in the incidence of other grade 3-4 adverse events between the two groups, suggesting that capecitabine maintenance therapy). The increase in hand-foot skin reaction is similar to the results reported in published meta-analyses by [19], Zhan Wang [6], J. Zhu [20], Z. Wu [21] and others. There was no signi cant difference in the incidence of other grade 3-4 adverse events between the two groups, suggesting that capecitabine maintenance therapy is a safe method.…”

Section: Safety Of Capecitabinesupporting

confidence: 88%

Does capecitabine maintenance therapy versus active monitoring confer a survival benefit after first-line treatment of metastatic colorectal cancer? A meta-analysis of randomized controlled trials

Li¹,

Chen

Jin

et al. 2022

Preprint

View full text Add to dashboard Cite

Background The maintenance treatment of metastatic colorectal cancer (mCRC) after first-line treatment is still controversial. Meta analysis was used to analyze whether there was survival benefit after first-line treatment of mCRC from the effectiveness and safety of capecitabine maintenance treatment. Methods In April, 2022, the following biomedical electronic databases were searched: PubMed, EMBASE, Google Scholar and Cochrane Library, including capecitabine maintenance therapy versus active monitoring randomized controlled trials (RCTs) and clinical trials (CT) of mCRC patients after first-line treatment. The primary outcome was progression free survival (PFS) of capecitabine maintenance therapy, and secondary outcomes included overall survival (OS), toxicity, and BRAF and RAS gene mutation status. Extract the hazard ratio (HR) of 95% confidence interval (CI) or HR data that can calculate 95% confidence interval (CI). All data were analyzed by Revman5.4 software. Results Five eligible studies included 1672 patients. Meta analysis showed that capecitabine maintenance therapy had more significant benefits for PFS than active monitoring PFS (HR 0.59; 95%CI: 0.52–0.66; P < 0.00001); In addition, capecitabine maintenance therapy was also beneficial to OS (HR 0.85; 95% CI: 0.76–0.95; p = 0.003). Subgroup analysis showed that BRAF/RAS wild-type patients were more likely to benefit from capecitabine maintenance, based on the significant interaction between BRAF/RAS status (P = 0.002). The most common adverse reaction was hand-foot skin reaction to capecitabine maintenance therapy compared with active monitoring (2.3% vs 0.4%; OR 5.53, 95%CI: 1.42–21.58, I2 = 0%, P = 0.01) was slightly increased. Conclusion This meta-analysis suggests that capecitabine was beneficial in PFS and OS compared with active monitoring. Adverse reactions are common but acceptable. Subgroup analysis showed that the differential effect of capecitabine maintenance treatment was beneficial to BARF/RAS wild-type patients. In specific cases, capecitabine monotherapy maintenance therapy can be considered, such as cumulative toxicity to fluoropyrimidine or patient rejection, especially for BRAF/RAS wild-type patients.

show abstract

Section: Safety Of Capecitabinesupporting

confidence: 88%

Does capecitabine maintenance therapy versus active monitoring confer a survival benefit after first-line treatment of metastatic colorectal cancer? A meta-analysis of randomized controlled trials

Li¹,

Chen

Jin

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Radical surgical treatment can cause surgery-related pain and result in various gastrointestinal symptoms, including nausea, vomiting, and bloating. 44 , 45 Patients with lower levels of literacy may struggle to follow symptom management recommendations provided by their care providers. Strong social support has been shown to have a positive impact on cancer prognosis as it enables patients feel emotionally supported during treatment.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy-related symptom networks in distinct subgroups of Chinese patients with gastric cancer

Li,

Zou,

Zhang

et al. 2024

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

“…Notably, when chemotherapy was resumed, fluoropyrimidine was switched from S-1 to capecitabine. The reason was that capecitabine as reported to cause less oral mucositis than S-1 in a comparison of adverse events between S-1 and capecitabine (Zhang et al 2021).…”

Section: Discussionmentioning

confidence: 99%

A case of tongue swelling after S-1, oxaliplatin, and trastuzumab for HER2-positive gastric cancer

Abe,

Sumiya,

Tsuji

et al. 2023

Bull Natl Res Cent

View full text Add to dashboard Cite

Background We report a case of a patient with HER2-positive gastric cancer with marked tongue swelling during the second cycle of S-1, oxaliplatin, and trastuzumab. Case presentation The patient was a 74-year-old male, who was taking an angiotensin II receptor blocker (ARB) for pre-existing hypertension, with no history of allergies, diagnosed with HER2-positive gastric cancer, treated with tegafur, gimeracil, and oteracil potassium (S-1) and oxaliplatin for the first cycle, and trastuzumab was added from the second cycle. Three weeks after initiation, during an outpatient visit, grade 2 oral mucositis and significant enlargement of the patient's tongue were observed. Due to the risk of airway obstruction, the patient was referred to an otolaryngologist. After examination, hereditary angioedema was ruled out, and treatment was discontinued in view of ARB-induced angioedema. However, the tongue swelling did not improve markedly. Considering disease progression due to the discontinuation of chemotherapy, it was decided to change S-1 to capecitabine and continue treatment, and chemotherapy was resumed. Conclusions Angioedema has been reported to be hereditary and drug-related, and angiotensin-converting enzyme (ACE) inhibitors and ARBs have also been reported to lead to drug-related adverse events. Since the patient had oral mucositis at the time of onset and was taking an ARB, it is thought that oxaliplatin and S-1(SOX), and trastuzumab during ARB therapy induced oral mucositis, leading to the development of angioedema.

show abstract

Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis

Cited by 5 publications

References 29 publications

Does capecitabine maintenance therapy versus active monitoring confer a survival benefit after first-line treatment of metastatic colorectal cancer? A meta-analysis of randomized controlled trials

Does capecitabine maintenance therapy versus active monitoring confer a survival benefit after first-line treatment of metastatic colorectal cancer? A meta-analysis of randomized controlled trials

Chemotherapy-related symptom networks in distinct subgroups of Chinese patients with gastric cancer

A case of tongue swelling after S-1, oxaliplatin, and trastuzumab for HER2-positive gastric cancer

Contact Info

Product

Resources

About